Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback